Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Other Non-Current Liabilities came in at $363000.0 in Q1 2026, up 46.96% YoY from $247000.0 in Q1 2025, and up 28.27% on a QoQ basis from $283000.0 in Q4 2025.
Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Other Non-Current Liabilities data on file, last reported at $363000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 46.96% year-over-year to $363000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363000.0 (up 46.96% YoY) and the FY2025 annual result came in at $283000.0, down 46.3% from the prior year.
- Other Non-Current Liabilities improved to $363000.0 in Q1 2026, from $283000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $15.8 million in Q1 2022 to a low of $247000.0 in Q1 2025.
- A 5-year average of $3.0 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 92.24% — and 2024, when it surged 70.76%.
- Tracing FATE's Other Non-Current Liabilities over 5 years: stood at $3.9 million in 2022, then tumbled by 65.14% to $1.3 million in 2023, then plunged by 60.85% to $527000.0 in 2024, then plunged by 46.3% to $283000.0 in 2025, then rose by 28.27% to $363000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $363000.0 (Q1 2026), $283000.0 (Q4 2025), and $410000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 363,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 410,000.00 |
| Jun 30, 2025 | 320,000.00 |
| Mar 31, 2025 | 247,000.00 |
| Dec 31, 2024 | 527,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 701,000.00 |
| Jun 30, 2023 | 1.75 Mn |
| Mar 31, 2023 | 2.14 Mn |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 9.04 Mn |
| Jun 30, 2022 | 9.93 Mn |
| Mar 31, 2022 | 15.81 Mn |
| Dec 31, 2021 | 24.17 Mn |
| Sep 30, 2021 | 24.63 Mn |
| Jun 30, 2021 | 12.87 Mn |